Eli Lilly and Co. plans to expand its global R&D headquarters in Indianapolis, IN, adding 130,000 sq.-ft. to its existing complex. The $70 million investment will feature a multi-disciplinary lab that facilitates collaboration across multiple research functions. The new building is part of Lilly’s continued growth of its Indianapolis footprint, which included a $400 million expansion initiated in 2013 to increase its insulin manufacturing capacity. When complete in 2017, the new bui...